Azithromycin is one of the most frequently prescribed antibiotics in the world, and one of the most frequently misunderstood. This article sets out what controlled studies, large registry cohorts, and regulatory safety reviews actually show about its use in three groups where questions come up most: children, pregnant and breastfeeding women, and older adults. The short answer is that azithromycin has a well-documented safety record in all three groups for its approved uses, with specific, named cautions that deserve a parent's or a patient's attention rather than alarm.

A drug drawn from the soil: what azithromycin is and how it works

Azithromycin belongs to the macrolide family, a class that traces its origin to erythromycin, first isolated in 1949 from a soil sample collected in the Philippines, from a bacterium called Streptomyces erythreus. Azithromycin itself was developed in the early 1980s by chemists at the Croatian pharmaceutical company Pliva, who modified erythromycin's structure to make a compound that lasted longer in tissue and caused less stomach upset. It was later licensed to Pfizer and sold as Zithromax. There is something worth pausing on here: some of medicine's most useful tools were not engineered from nothing but discovered, quietly present in ordinary dirt, waiting to be recognized. It is a small but real reminder that the created order carries provision within it.

Mechanically, azithromycin works by binding to the bacterial ribosome's 50S subunit and interrupting protein synthesis, which stops bacteria from multiplying. It concentrates well inside tissues and white blood cells, which is why a short course, often five days, can achieve effects that would require a longer course of many other antibiotics. That convenience is exactly why the "Z-pack" nickname stuck, and why it became a default choice for many respiratory infections, sometimes beyond where it was the best choice.

Children and the "Z-Pack": dosing, real uses, and sensible caution

Azithromycin is approved by the FDA for several pediatric indications, including acute otitis media (middle ear infection), community-acquired pneumonia, and streptococcal pharyngitis as an alternative for children allergic to penicillin, generally from six months of age depending on the formulation and indication. It is also a preferred antibiotic for treating and preventing pertussis (whooping cough) in infants, including newborns, because it is tolerated better than erythromycin in this age group.

Pediatric dosing is calculated by body weight, not by a fixed tablet size. This is worth stating plainly because it corrects a common assumption: a 250 mg tablet is not "the children's dose" of anything. Typical regimens include:

Because children's weights vary so widely, the oral suspension is dosed individually by a physician or pharmacist; a "Z-pack," in the sense of the fixed adult dose-pack sold for a five-day course, is designed for adults and larger adolescents, not for young children.

One specific caution deserves mention. Large cohort studies drawn from Scandinavian national health registries have found an increased relative risk of infantile hypertrophic pyloric stenosis, a condition causing forceful vomiting from a thickened stomach outlet, when macrolide antibiotics, including azithromycin, are given in the first two weeks of life. The absolute risk remains low, and azithromycin is still generally preferred over erythromycin for treating pertussis in newborns because it works better and is gentler on the stomach. Parents of very young infants given a macrolide should simply know to watch for persistent, forceful vomiting and mention it to their pediatrician promptly.

It is also worth saying clearly that azithromycin does nothing for viral illness. Most sore throats, coughs, and colds in children are viral, and antibiotics given for them carry real downsides, diarrhea, disruption of a child's developing gut flora, and a contribution to antibiotic resistance in the wider community, without any benefit. Asking a pediatrician "does my child actually need this" is not obstructionist; it is good stewardship of a young body and of antibiotics that the next generation will also need to work.

Pregnancy: what the evidence actually shows

Azithromycin has one of the more reassuring safety profiles among antibiotics used in pregnancy, and it has a specific, important job there. The Centers for Disease Control and Prevention recommends a single 1-gram dose of azithromycin as the preferred treatment for chlamydia infection during pregnancy, precisely because untreated chlamydia carries its own real risks, including preterm birth and neonatal eye and lung infection at delivery. Azithromycin is also used, in some protocols, alongside other measures in the management of preterm premature rupture of membranes, and as an alternative for penicillin-allergic patients needing Group B strep-related care around delivery.

On the broader question of birth defects, large observational studies, notably cohort analyses drawn from Danish national health registries comparing tens of thousands of macrolide-exposed pregnancies against penicillin-exposed pregnancies, have not found a statistically significant increase in major malformations associated with macrolide use in general. Earlier concern centered specifically on erythromycin, where some studies suggested a possible link to cardiovascular malformations when taken very early in pregnancy; that specific signal has not been clearly reproduced for azithromycin.

It is honest to note the limits of this evidence rather than overstate it. No one runs a randomized, placebo-controlled trial giving antibiotics to pregnant women purely to test safety, for good ethical reason, so what we have is observational registry data: large, useful, and reassuring, but not the same tier of evidence as a controlled trial. That is a reasonable basis for a physician and patient to weigh a real infection needing treatment against a residual, unquantified uncertainty, which is exactly the kind of decision that belongs between a pregnant woman and her own doctor rather than being made by a general rule.

Breastfeeding mothers: what actually passes into milk

According to LactMed, the National Institutes of Health's database on drugs and lactation, azithromycin passes into breast milk only in small amounts relative to the doses used to treat infants directly. It is generally considered compatible with breastfeeding by pediatric and lactation authorities, and a standard course does not require interrupting nursing or discarding milk. The main thing to watch for is a mild, self-limited change in the infant's stool, occasional loose stools or mild diarrhea, which reflects the small amount of antibiotic reaching the infant's gut rather than any deeper harm. If a nursing mother needs azithromycin for a genuine bacterial infection, the evidence does not support avoiding breastfeeding on account of the drug.

Older adults: the cardiac question and other real considerations

The most consequential piece of evidence in this area is a retrospective cohort study led by researchers at Vanderbilt University, published in the New England Journal of Medicine around 2012, using Tennessee Medicaid records covering millions of antibiotic courses. It found a small but measurable increase in cardiovascular deaths among patients taking a five-day course of azithromycin compared with those taking amoxicillin or no antibiotic, with the increased risk concentrated heavily among patients who already had significant underlying cardiovascular risk. Off the back of that and related research, the FDA issued a formal Drug Safety Communication in 2013 warning that azithromycin can prolong the QT interval, an electrical property of the heartbeat, and in rare cases lead to a dangerous, potentially fatal irregular rhythm known as torsades de pointes. The risk is highest in people who already have a prolonged QT interval, low blood potassium or magnesium, a slow heart rate, or who are taking other drugs that also affect heart rhythm, such as certain antiarrhythmics or antipsychotics.

This matters more in older adults simply because heart disease, electrolyte problems, and multiple medications are all more common with age. Sensible precautions for an older patient starting azithromycin include:

Beyond the cardiac question, older adults face a somewhat higher baseline risk of Clostridioides difficile colitis with any antibiotic course, azithromycin included, and clinicians generally avoid unnecessary or repeated courses for that reason. Azithromycin is cleared mainly through the liver and bile rather than the kidneys, so dose adjustment for reduced kidney function is usually unnecessary except in severe impairment, though significant liver disease warrants caution. None of this means azithromycin is unsuitable for older patients; it means the decision benefits from a physician who knows the patient's full cardiac and medication history, which is precisely the kind of informed, individualized judgment this drug calls for at any age.

Key takeaway: Azithromycin has a well-established safety record for its approved uses in children, pregnancy, breastfeeding, and older adults, provided dosing is weight-based in children, genuine infection justifies its use in pregnancy, and cardiac history and interacting medications are reviewed carefully with a physician in older patients.